期刊文献+

PFT-α对结肠上皮细胞凋亡和周期的影响及机制探讨 被引量:2

Effects of PFT-α on proliferation and apoptosis of large intestinal epithelial cells and its mechanisms
下载PDF
导出
摘要 目的探讨p53抑制剂(p-fiftythreeinhibitor-alpha,PFT-α)对结肠上皮细胞凋亡、周期的影响及机制。研究PFT-α对热化疗损伤结肠上皮细胞的影响。方法顺铂联合温热处理原代培养结肠上皮细胞30min,对比加入不同浓度PFT-α后,AnnexinV-FITC/PI染色,流式细胞仪检测细胞凋亡。PI染色检测细胞周期。Westernblot检测结肠上皮细胞CyclinB1和Cdc2(Tyr15)表达。结果不同浓度PFT-α作用于热化疗处理的结肠上皮细胞后,细胞凋亡率下降且呈剂量依赖性。流式细胞仪细胞周期分析显示在运用PFT-α后,结肠上皮细胞的G2/M延长,CyclinB1和Cdc2(Tyr15)蛋白表达随PFT-α的剂量升高而逐渐增强。结论PFT-α可能通过促进CyclinB1蛋白表达,Cdc2(Tyr15)磷酸化水平升高,降低CyclinB1/Cdc2活性,细胞停滞于G2/M期,减轻热化疗对结肠上皮细胞的损伤。 Objective To investigate the effect of PFT-α on proliferation, cell cycle and apoptosis of large intestinal epithelial cells in vitro . Methods The large intestinal epithelial cells were treated with hyperthermic (43℃) and cisplatin ( 10 mg/L) for 30 min in the absence or presence of different dosage of PFT-α. The rate of apoptosis was detected using flow cytometry (FCM) by Annexin V-FITC and propidium iodide (PI) double labeling technique. Cell cycle was analyzed by using FCM with PI labeling technique. The expression of CyclinB1 and Cdc2 (Tyr15) were measured by Western blot. Results After treatment of large intestinal epithelial cells with different concentrations of PFT a and thermochemotherapy, the apoptosis rate was decreased. FCM analysis showed an increase in G2/M phase cell fraction. Western blot displayed significantly higher protein levels of CyelinB1 and Cdc2(Tyr15) than those in the hyperthermic chemotherapy group. Conclusions PFT-α can protect large intestinal epithelial cells against thermochemotherapy-induced damages. The mechanisms of the protective effect of PFT-α is most likely due to the decreased apoptotic large intestinal epithelial cells, and the increased G2/M phase cell fraction and protein of CyclinBl.
出处 《消化外科》 CSCD 2005年第5期350-353,共4页 Journal of Digestive Surgery
关键词 PFT-Α 肠上皮细胞p53 CyclinB1/Cdc2 PFT-α intestinal epithelial cells p53 CyelinB1/Cdc2
  • 相关文献

参考文献11

  • 1Komarova EA, Gudkov AV. Chemoprotection from p53-dependent apoptosis: potential clinical applications of the p53 inhibitors[J]. Biochem Pharmacol,2001,62(6): 657-667
  • 2Komarova EA, Gudkov AV. Suppression of p53: a new approach to overcome side effects of antitumor therapy[J]. Biochemistry (Mosc) ,2000,65(2) :41-48
  • 3van der Vange N, van Goethem AR, Zoetmulder FA,et al . Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot[J]. Eur J Surg Oncol,2000,26(7):663-668
  • 4Shen P, Levine EA, Hall J, et al . Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after eytoreductive surgery for patients with peritoneal carcinomatosis[J]. Arch Surg,2003,138(1) :26-33
  • 5Grossmann J, Walther K, Artinger M, et al . Progress on isolation and short-term ex-vivo culture of highly purified non-apoptotic human intestinal epithelial cells (IEC)[J]. Eur J Cell Biol,2003,82(5):262-270
  • 6Zhang M, Liu W, Ding D, et al . Pifithrin-alpha suppresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis [J]. Neuroscience, 2003,120 ( 1 ): 191 - 205
  • 7Liu X, Chua CC, Gao J, et al . Pifithrin-alpha protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice[J]. Am J Physiol Heart Circ Physiol,2004,286(3): H933- 939
  • 8Yang J, Song H, Walsh S, et al . Combinatorial control of cyclin B1 nuclear trafficking through phosphorylation at multiple sites[J]. J Biol Chem, 2001,276(5): 3604 - 3609
  • 9Fimognari C, Nusse M, Berti F, et al . A mixture of isothiocyanates induces cyclin B1- and p53-mediated cellcycle arrest and apoptosis of human T lymphoblastoid cells[J]. Mutat Res, 2004,554(1 - 2): 205 - 214
  • 10Paradis F, Vigneault C, Robert C, et al . RNA interference as a tool to study gene function in bovine oocytes[J]. Mol Reprod Dev,2005,70(2) : 111-121

同被引文献25

  • 1van der Vange N,van Goethem A R,Zoetmulder F A,et al.Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer:a feasibility pilot[J].Eur J Surg Oncol,2000,26(7):663-668.
  • 2Shen P,Levine E A,Hall J,et al.Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis[J].Arch Surg,2003,138(1):26-33.
  • 3Komarov P G,Komarova E A,Kondratov R V,et al.A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy[J].Science,1999,285(5434):1733-1737.
  • 4Komarova E A,Gudkov A V.Chemoprotection from p53-dependent apoptosis:potential clinical applications of the p53 inhibitors[J].Biochem Pharmacol,2001,62(6):657-667.
  • 5Wu Y J,Muldoon L L,Neuwelt E A.The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway[J].J Pharmacol Exp Ther,2005,312(2):424-431.
  • 6Camphausen K,Moses M A,Menard C,et al.Radiation abscopal antitumor effect is mediated through p53[J].Cancer Res,2003,63(8):1990-1993.
  • 7Kudo M,Asao T,Hashimoto S,et al.Closed continuous hyperthermic peritoneal perfusion model in mice with peritoneal dissemination of colon 26[J].Int J Hyperthermia,2004,20(4):441-450.
  • 8Komarova E A,Gudkov A V.Suppression of p53:a new approach to overcome side effects of antitumor therapy[J].Biochemistry (Mosc),2000,65(1):41-48.
  • 9Ryu K S,Kim J H,Ko H S,et al.Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer[J].Gynecol Oncol,2004,94(2):325-332.
  • 10Piso P,Dahlke M H,Loss M,et al.Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer[J].World J Surg Onco,2004,2(1):21-21.

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部